Skip to main content

Table 3 Estimated odds of serious infection for selecteda treatment strategies compared to anti-tumor necrosis factor biologics

From: Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

Treatment strategy Comparator Odds ratio Standard error 95% Confidence interval
Adalimumab Infliximab 0.57 0.57 0.18 1.74
Certolizumab pegol Infliximab 1.74 0.67 0.47 6.53
Natalizumab Infliximab 0.58 0.60 0.18 1.88
Ustekinumab Infliximab 0.30 0.66 0.08 1.08
Vedolizumab Infliximab 0.55 0.58 0.18 1.74
Golimumab Infliximab 1.26 0.80 0.26 6.05
Infliximab + azathioprine/6MP Infliximab 0.81 0.50 0.30 2.17
Infliximab + azathioprine/6MP + prednisone Infliximab 0.23 2.29 0.00 20.82
Certolizumab pegol Adalimumab 3.08 0.62 0.91 10.37
Natalizumab Adalimumab 1.03 0.54 0.36 2.94
Ustekinumab Adalimumab 0.52 0.60 0.16 1.71
Vedolizumab Adalimumab 0.98 0.52 0.35 2.71
Golimumab Adalimumab 2.22 0.76 0.50 9.78
Natalizumab Certolizumab pegol 0.34 0.64 0.10 1.18
Ustekinumab Certolizumab pegol 0.17 0.70 0.04 0.67
Vedolizumab Certolizumab pegol 0.32 0.63 0.09 1.09
Golimumab Certolizumab pegol 0.72 0.84 0.14 3.71
  1. Abbreviations: 6MP 6-mercaptopurine, MMF mycophenolate mofetil
  2. aOther group comparisons can be found in Additional file 3: Table S3
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us